ABBV · 8-K · 20260903PR104940
Acquisition / Partnership / Divestiture
AbbVie Inc. · 2026-09-03 · Importance 71 · Surprise 60 · In source text
AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026, bringing Apogee into AbbVie. Apogee shareholders received $135.11 per share in cash, representing total equity value of approximately $10.9 billion. Apogee common stock stopped trading on Nasdaq before market open on September 3, 2026. AbbVie expects the transaction to reduce adjusted diluted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032.
Key facts
- AbbVie expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year). source
- AbbVie expects the acquisition to negatively impact adjusted diluted EPS by approximately $0.46 in 2027. source
- AbbVie expects accretion from the acquisition to begin in 2032. source
- AbbVie completed its acquisition of Apogee Therapeutics, Inc. on Sept. 3, 2026. source
- AbbVie has acquired all outstanding Apogee common stock for $135.11 per share in cash. source
- Apogee's common stock ceased trading on the NASDAQ stock exchange prior to market open on Sept. 3, 2026. source
- The acquisition deepens AbbVie's immunology pipeline with assets targeting dermatologic, respiratory and other inflammatory and immunological diseases. source
- Apogee shareholders received $135.11 per share in cash under the terms of the agreement. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | probable | — | AbbVie expects the acquisition to negatively impact adjusted diluted EPS by approximately $0.46 in 2027. |
| net_income | positive | probable | — | AbbVie expects accretion from the acquisition to begin in 2032. |